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Abstract
Objectives: The purpose of this study is to examine the relationship between 5-HTTLPR polymorphism (44-bp insertion/
deletion polymorphism of serotonin transporter gene) and methylphenidate (MPH) treatment response, as well as the
association between the adverse events of MPH treatment and 5-HTTLPR polymorphism in children with attention-deficit/
hyperactivity disorder (ADHD).
Methods: A total of 114 children with ADHD (mean age 9.08 – 1.94 years) were recruited from the child psychiatric clinic
in a hospital in South Korea.We have extracted the genomic DNA of the subjects from their blood lymphocytes and analyzed
5-HTTLPR polymorphism of the SLC6A4 gene. All children were treated withMPH for 8 weeks, with clinicians monitoring
both the improvement of ADHD symptoms and the side effects. We compared the response to MPH treatment and adverse
events among those with the genotype of 5-HRRLPR polymorphism.
Results:Therewas no significant association between the 5-HTTLPRgenotype and the response toMPH treatment in children
with ADHD. Subjects with the S/L+L/L genotype tended to have tics and nail biting (respectively, p < 0.001, p = 0.017).
Conclusions: The results of this study do not support the association between the 5-HTTLPR polymorphism and treatment
response with MPH in ADHD. However, our findings suggest the association between 5-HTTLPR polymorphism and the
occurrence of tics and nail-biting as an adverse event of methylphenidate. This may aid in our understanding of the genetic
contribution and genetic susceptibility of a particular allele in those ADHD patients with tics or nail biting.
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is themost common psychiatric disorder in children and adolescents
(American Psychiatric Association 2013). Its worldwide preva-
lence is 5.29% (Polanczyk et al. 2007a). ADHD is known as a
highly polygenic disorder. Its heritability is as high as 0.76 (Bie-
derman and Faraone 2005). Previous genetic studies have investi-
gated specific genes related to the etiology of ADHD. The complex
interplay of genes related to dopamine, norepinephrine, and sero-
tonin regulation in the brain is known to be the genetic etiology of
ADHD (Cross-Disorder Group of the Psychiatric Genomics Con-
sortium 2013). In particular, the involvement of genes related to the
regulation of dopamine system such as the dopamine transporter
(DAT) and D4 dopamine receptor (DRD4) genes in the patho-
genesis of ADHD were supported by many previous studies and
confirmed by several meta-analysis studies (Purper-Ouakil et al.
2005; Gizer et al. 2009). However, these findings only explained a
small portion of ADHD heritability, because their effect sizes were
small. In addition, each susceptibility gene is likely to have low
penetrance (Gizer et al. 2009; Akutagava-Martins et al. 2013).
Methylphenidate (MPH) has been reported to improve core
symptoms of ADHD. However, *30% of patients did not show
satisfactory clinical response to MPH treatment (Swanson et al.
2002). Interindividual variability of clinical response to the same
pharmacological agent has been reported in previous investigations
(Husain et al. 2007). Identifying specific genetic variants underlying
the clinical response to treatment is likely to explain the genetic
contributor that partially affects the interindividual variability (Ma-
sellis et al. 2002). Further, the effort to investigate the genetic
mechanism of response to medications might help us understand the
underlying pathological process of ADHD. So far, pharmacogenetic
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research of ADHD has been focused on genes related to the dopa-
mine and noradrenalin (NA) system, the primary site of action of
MPH. Representatively, genetic polymorphisms of DAT (Winsberg
and Comings 1999; Cheon et al. 2005; Stein et al. 2005; Joober et al.
2007), dopamine receptor DRD2 (Leddy et al. 2009), DRD4 (Ha-
marman et al. 2004; Cheon et al. 2007; Ji et al. 2013), and DRD5
(Tahir et al. 2000) have been reported to contribute to the response to
MPH treatment. For Korean children with ADHD, subjects with 4/4
genotype at DRD4 (homozygosity of the four repeat allele) were
reported to have better response to MPH compared with other ge-
notypes (Cheon et al. 2007). However, it was also reported that there
was no association between the four repeat allele of the DRD4 gene
and the response to MPH treatment ( Ji et al. 2013). Although genes
in the noradrenergic pathway have been examined less frequently
than dopamine genes, prior studies mainly involved the G allele at
the a-2a-adrenergic receptor (ADRA2A) gene polymorphism (Po-
lanczyk et al. 2007b; da Silva et al. 2008; Cheon et al. 2009) and
norepinephrine transporter (NET) polymorphism (Yang et al. 2004).
In line with these findings, better response to MPH was shown by
homozygosity for the ADRA2A G allele (G/G) in children with
ADHD in Korea (Cheon et al. 2009). In order to have a compre-
hensive understanding of ADHD, it is important to acknowledge the
interaction of serotonergic system related to emotion and impulsivity
regulation as well as the dopamine and norepinephrine system re-
lated to cognitive and reward processing (Nigg and Casey 2005).
5-HTTLPR (44-bp insertion/deletion polymorphism of seroto-
nin transporter gene), a candidate gene for ADHD susceptibility
that regulates serotonergic neurotransmission, is located on the
long arm of chromosome 17 (Gelernter et al. 1995). 5-HTTLPR
involves two common variants: S (short) allele and L (long) allele.
The L allele compared with the S allele has increased 5-HTT
mRNA expression that leads to faster serotonin reuptake from the
serotonin transporter, which in turn results in low serotonin con-
centration in the synaptic clefts (Lesch et al. 1994; Heils et al.
1996). It has been reported that the S allele may be related to
internalizing symptoms such as depression and anxiety, whereas
the L allele may be related to externalizing symptoms such as
impulsivity and aggression. In addition, more L allele carriers were
found in children with ADHD (Cadoret et al. 2003; Kent et al.
2002). Recently, it has been suggested that the S allele at
5-HTTLPR polymorphism modulates an individual’s response to
environmental stress, with the S allele representing a higher sen-
sitivity to stress, indicating that the S allele can be considered a
susceptibility gene in ADHD in response to a high-stress environ-
ment (Caspi et al. 2010). For example, individuals who were
S allele carriers showed a heightened vulnerability to ADHD
within a high-stress environment (Muller et al. 2008; Retz et al. 2008).
Many pharmacological and neurobiological studieswere conducted
on the close interaction between dopamine and serotonin. Seeger et al.
(2001) have found that children with hyperkinetic disorder (Interna-
tional Classification of Diseases, 10th Revision [ICD-10]) with the
DRD4 and L/L genotype of 5-HTTLPR show a better treatment re-
sponse toMPH (Seeger et al. 2001). However, two subsequent studies
reported that 5-HTTLPR was not associated with MPH treatment re-
sponse (Zeni et al. 2007; Tharoor et al. 2008). Nevertheless, one recent
study suggested that ADHD children with the L/L genotype showed a
better response to MPH when behavioral problems of ADHD were
examined (Thakur et al. 2010). 5-HTTLPRwas recently found to be a
candidate gene in Tourette disorder as well as ADHD. New onset or
aggravation of tic symptoms reported in Tourette patients with the L
allele could be because 5-HTTLPR polymorphism indirectly affected
the dopaminergic system. Some studies reported that change in the
serotonin receptor affected by different 5-HTTLPR polymorphisms
would increase the secretion of dopamine, affecting the onset of
Tourette disorder (Cath et al. 2001; Moya et al. 2013). In order to
provide explanation for these inconsistencies in previous research re-
sults, the present study aimed to examine the relationship between 5-
HTTLPR polymorphism and MPH treatment response, as well as the
association between the side effects ofMPH treatment and 5-HTTLPR
polymorphism in children with ADHD.
Materials and Methods
Subjects
The present study enrolled ADHD children (age 6–15 years) from
child psychiatric clinics of two university hospitals in Korea. Inclu-
sion criteria for the study were: 1) Being diagnosed with ADHD
according toDiagnostic and Statistical Manual of Mental Disorders,
4th ed. (DSM-IV) Diagnostic Criteria of Mental Disorders (Ameri-
can Psychiatric Association 1994), 2) their parents/guardians agreed
to let them participate in the study with informed consent, and 3) had
no history of exposure to psychostimulants such as MPH prior to the
study participation. Exclusion criteria were: 1) A past or present
history of brain damage or convulsive disorder; 2) mental retardation,
autism, language difficulties, or developmental problems including
learning disability; 3) not having agreement from parents/guardians
for them to participate in the study. This study was approved by the
Institutional Review Board for human subjects.
Diagnostic and evaluation tools of clinical symptoms
The Korean version of the Kiddie-Schedule for Affective
Disorders and Schizophrenia-Present and Lifetime Version
(K-SADS-PL-K). K-SADS-PL was developed for the psychiatric
diagnosis of children and adolescents between 6 and 17 years of age
(Kaufman et al. 1997). This semistructured interview was used to
assess the presence of current and past psychiatric disorders. This
measure has been translated into Korean. Its reliability and validity
on ADHD, tic disorder, and oppositional defiant disorder (ODD) for
Korean children and adolescents were proven by Kim et al. (2004).
ADHD Rating Scale-IV (ARS). DuPaul et al. (1998) devel-
oped the ARS scale in order to measure the severity of ADHD
symptoms according to the DSM-IV Diagnostic Criteria of Mental
Disorders (DuPaul et al. 1998). This scale had 18 items that were
divided into nine inattention and nine hyperactivity/impulsivity
subscales. Each item was measured on a four point scale ranging
from 0 to 3. The Korean version of ARS was developed and stan-
dardized by So et al. (2002).
Clinical Global Impressions – Improvement (CGI-I). CGI
is composed of a symptom severity scale (CGI-S) and symptom
improvement scale (CGI-I). CGI-I is a seven point scale requiring
clinicians to assess how much the patient’s illness has improved or
worsened relative to a baseline state at the beginning of the inter-
vention (Guy 1976). On the 7 point scale, 1 point was used for very
much improved; 2 points for much improved; 3 for minimally
improved; 4 for no change; 5 for minimally worse; 6 for much
worse; and 7 for very much worse.
MPH administration and treatment response
All subjects participating in this study were administeredMPH for
8weeks.MPHdosagewas increased until sufficient therapeutic effect
was observed in the subjects. The therapeutic effect was determined
by the degree of improvement and side effects reported by the parents.
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We adjusted the MPH doses at visit 1 (1st week), visit 2 (2nd week),
visit 3 (4th week), and visit 4 (6th week) and performed posttreatment
assessments at visit 5 (8thweek). The posttreatment assessmentswere
evaluated using the ARS score reported by parents and the CGI score
rated by clinician. A clinical response to the treatmentwas determined
as follows. A ‘‘good’’ response indicated an improvement of >50%
from the baseline ARS score, and an improvement in CGI-I score of 1
or 2 points after 8weeks of treatment. A ‘‘poor’’ response indicated an
improvement in the ARS scores of <50% and a CGI-I score in the
range of 3–7 points. All procedureswere performed by clinicians who
had no information about the results of 5-HTTLPR genotype analysis.
Assessment for adverse events induced by MPH
Clinicians identified the most common adverse effects such as
sleep disturbance, loss of appetite, tics, and nail biting. Adverse ef-
fects were also reported by subjects and their parents at each visit.
Those who showed a ‘‘marked’’ adverse event according to the cli-
nician’s judgment in the 8th week were considered as those who
developed adverse effects related to the MPH treatment in this study.
‘‘Marked severity’’ was defined as a symptom severity that caused the
impairment of functioning or social embarrassment to a degree that
the benefits of medication must be considered to justify the risks of
continuing medication (Pelham 1993). More specifically, the fre-
quency of adverse events wasmore than three times perweek, and the
intensity of adverse events were severe enough to reduce conformity
to medication, and the duration was reported through all 8 weeks of
MPH treatment. However, ‘‘tics’’ as an adverse event was described
as a categorical variable, dividing them into a group of ‘‘new onset or
aggravation of tics’’ and a group of ‘‘no change of tics or no tics.’’
Serotonin transporter gene (SLC6A4) genotyping
Genomic DNA was extracted from whole blood lymphocytes
using Genomic DNA Extraction Kit (Bioneer, Korea). The 5-
HTTLPR polymorphism of the SLC6A4 gene was analyzed
by polymerase chain reaction (PCR). Oligonucleotide primers
(5¢-GGCGTTGCCGCT CTGAATGC-3¢ and 5¢-GAGGGACTG
AGC TGG ACA ACC A-3¢) were used in PCR. Allele resolution
was confirmed by agarose gel electrophoresis.
Statistical analysis
Descriptive statistics in numbers and percentages were used to
analyze demographic and the clinical characteristics of the partic-
ipants. v2 test or Fisher’s exact test was used to examine the asso-
ciation between the genotype of 5-HTTLPR and MPH treatment
response or between the genotype of 5-HTTLPR and the adverse
events after MPH treatment response. A p value of 0.0125 (two
tailed) was chosen as the Bonferroni-corrected significance
threshold to adjust for multiple comparisons in four adverse events
related toMPH treatment. SPSS 20.0 software (SPSS Inc., Chicago,
IL) was used for statistical analysis.
Results
Demographic and clinical characteristics
This study initially included 131 children with ADHD, but 17
participants dropped out because of adverse events; in 15 (11.5%)
these were related to MPH treatment (7 for loss of appetite, 5 for
sleep disturbance, 3 for depressed mood/irritability). Another two
were excluded from the final analysis because of blood storage
problem. The mean age of the 114 ADHD subjects used in this
study was 9.08 – 1.94 years. The 114 subjects included 95 (83.3%)
boys and 19 (16.7%) girls. Of the 114 subjects with ADHD, 70
(60.9%) had the SLC6A4 SSs genotype, 40 (34.8%) had the S/L
genotype, and 4 (3.5%) had the L/L genotype. There was no sig-
nificant difference in the demographic or clinical characteristics
between patients with S/S and those with S/L+L/L genotypes
(Table 1). The genotypic distribution of 5-HTTLPR polymorphism
Table 1. Comparison of Demographic and Clinical Characteristics According to the Genotype of 5-HTTLPR
Characteristics
Total (% of total) S/S S/L+ L/L
p(n= 114) (n= 70) (n = 44)
Age (years) 9.08 – 1.94 8.99 – 1.99 9.23 – 1.89 0.674a
Male (%) 95(83.3%) 56(80.0%) 39(88.6%) 0.228b
FSIQ 104.78– 16.20 103.13– 17.56 107.31– 14.91 0.575a
ADHD subtype
Combined (% of each genotype) 49(43.0%) 25(35.7%) 24(54.5%)
Inattentive (% of each genotype) 53(46.5%) 37(52.9%) 16(36.4%) 0.139b
Hyperactive/Impulsive (% of each genotype) 12(10.5%) 8(11.4%) 4(9.1%)
Comorbidity
Conduct disorder (% of each genotype) 2(1.8%) 1(1.4%) 1(2.3%) 1.000b
ODD (% of each genotype) 5(4.4%) 1(1.4%) 3(6.8%) 0.297b
Mood (% of each genotype) 20(17.5%) 13(18.6%) 7(15.9%) 0.716b
Anxiety disorder (% of each genotype) 12(10.5%) 9(12.8%) 3(6.8%) 0.432b
Tic disorder (% of each genotype) 11(9.6%) 6(8.6%) 5(11.4%) 0.747b
ARS Baseline Scores
Total 32.19– 8.01 32.99– 7.70 30.93– 8.42 0.184a
Inattentive 16.67– 4.20 16.87– 4.36 16.34– 3.95 0.513a
Hyperactive/impulsivity 15.53– 6.29 16.11– 6.25 14.59– 6.30 0.209a
Mean dosage of MPH (mg/day) 29.47– 7.61 29.86– 7.51 28.84– 7.81 0.556a
aCalculated by one way analysis of variance test.
bCalculated by v2 test or Fisher exact test.
FSIQ: Full scale intelligence quotient; ADHD, attention-deficit/hyperactivity disorder; ODD, oppositional defiance disorder; ARS, ADHD Rating
Scale; MPH, methylphenidate.
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was consistent with the expected values of those computed from
Hardy–Weinberg Equilibrium (v2 = 0.352, df = 1, p= 0.55).
Correlation between the response to MPH treatment
and the 5-HTTLPR polymorphism
The mean MPH doses for the S/S group and for the S/L+L/L
group were not significantly different (Table 1). A total of 44
(62.9%) subjects with S/S genotype and 24 (54.5%) subjects with
S/L+L/L genotype showed good response to MPH treatment as
measured by the ARS. There were no significant group difference
either in response to MPH treatment when assessed by ARS
(v2 = 0.775, p= 0.379) or by CGI-I (v2= 0.910, p = 0.34, Table 2). In
addition, there was no significant difference between the changes in
ARS scores before and after MPH treatment, depending on the
genotype of 5-HTTLPR (t= 0.716, p= 0.461).
Adverse events after the use of MPH
After receiving MPH treatment, 9 (7.9%) and 20 (17.5%) subjects
reported sleep disturbances and loss of appetite, respectively (Table
3). There was no significant difference in adverse events between the
two groups. Nail biting was more frequently reported in the S/L+L/L
group (22.7%, n= 10) than in the S/S group (7.1%, n= 5). This dif-
ference was significant (v2= 5.743, p= 0.023). However, in a post-
hoc analysis, nail biting did not survive Bonferroni-corrected level of
significance (0.0125). In patients with the S/S genotype, nine (12.9%)
reported a new occurrence or aggravation of tics. In contrast, 20
(45.5%) patients with the S/L+L/L genotype had new onset of tics or
aggravated tics (v2= 15.136, p< 0.001, Table 3).
Discussion
Our results revealed that there was no significant association
between the 5-HTTLPR genotype and the clinical response toMPH
treatment in Korean children with ADHD. Although the association
between ADHD and 5-HTTLPR has already been reported, there
were only a few studies regarding the association between the
5-HTTLPR genotypes and the treatment response of MPH. How-
ever, those results were inconsistent.
Weizman et al. (1987) suggested that MPH treatment could re-
duce prolactin level. Shapira et al. (1992) showed that the increased
serotonin level from the selective serotonin reuptake inhibitor
(SSRI) injection caused the release of prolactin. In this context,
Seeger et al. investigated the change in prolactin level by creating
a group having both DRD4 and 5-HTTLPR polymorphisms from
children with hyperkinetic disorder (ICD-10). Their findings
showed that when MPH was administered in subjects with both the
DRD4-7 allele and the 5HTTLPR/L genotype, the prolactin level
was increased, but the degree of improvement in hyperactivity and
impulsivity was decreased (Seeger et al. 2001). Although it was not
a study solely on 5-HTTLPR, that study made it possible to predict
that 5-HTTLPRmight interact with the dopamine system and affect
the treatment response in ADHD.
Subsequently, Zeni et al. (2007) and Tharoor et al. (2008) re-
ported the absence of association between 5-HTTLPR and treatment
response in ADHD (Zeni et al. 2007; Tharoor et al. 2008). However,
these studies had some limitations, in that observations for clinical
response were made only for a relatively short period of time
(4 weeks), and assessments were retrospectively performed based
on parents’ subjective reports. In the most recent crossover study on
5-HTTLPR and the clinical response to MPH treatment (Thakur
et al. 2010), ADHD children with S/S genotypes (LG/LG, S/LG and
S/S) were improved even in a placebo condition. In contrast, pa-
tients with the L/L genotype (LA/LA) showed no improvement in a
placebo condition. However, they had sufficient improvement after
MPH treatment. In subjects with the S/L genotype (LG/LA and
S/LA), some improvement was made in both the placebo condition
and after MPH treatment, showing an intermediate profile between
Table 2. Association between 5-HTTLPR Genotype and Response to MPH Treatment in ADHD Subjects
Response to MPH
5-HTTLPR genotype
Total (% of total) pn (% of total within genotype) S/S (n = 70) S/L+L/L (n= 44)
Poor (ARS Change <50%) 26(37.1%) 20(45.5%) 46(40.4%) 0.379
Good (ARS Change ‡50%) 44(62.9%) 24(54.5%) 68(59.6%)
Poor (CGI score:3*7) 24(34.3%) 19(43.2%) 43(37.7%) 0.340
Good (CGI score:1 or 2) 46(65.7%) 25(56.8%) 71(62.3%)
v2 test was used for association analysis; significant at p< 0.05.
MPH: methylphenidate; ADHD, attention-deficit/hyperactivity disorder; ARS, ADHD Rating Scale; CGI, Clinical Global Impressions.
Table 3. Difference in the Adverse Events after the Use of MPH According to the Genotype of the 5-HTTLPR
Adverse events
5-HTTLPR Genotype
Total (% of total) pn (% of total within genotype) S/S (n= 70) S/L+ L/L (n = 44)
Difficulty falling asleep 6(8.6%) 3(6.8%) 9(7.9%) 0.517a
Decreased appetite 13(18.6%) 7(15.9%) 20(17.5%) 0.716a
Nail biting 5(7.1%) 10(22.7%) 15(13.2%) 0.023a
Tics after the use of MPH
New onset or tics aggravated 9(12.9%) 20(45.5%) 29(25.4%) <0.001b
No change or no tics 61(87.1%) 24(54.5%) 85(74.6%)
aThe v2 test was used of association, significant at p value< 0.05.
bAt a Bonferroni-adjusted level of significance ( p = 0.0125), significant differences in tics after the use of MPH.
MPH, methylphenidate.
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the S/S genotype and the L/L genotype. These results indicate that
the clinical response to MPH treatment was better when 5-HT
transmission of the LA allele became more efficient.
The discrepancy between this present study and previous studies
might be explained as follows. First, it may be because of polygenic
contribution or phenotypic heterogeneity. In the polygenic mode of
inheritance, each of multiple genes can contribute to a certain
phenotype as a small percentage (or has a small effect on risk).
Therefore, it might be difficult to reach statistical significance.
Second, we divided our samples into S/S and S/L+L/L genotypes
because of the limited number of subjects with L/L genotypes. As a
result, three-group comparison using the traditional grouping of
S/S, S/L, and L/L could not be conducted for our samples. In ad-
dition, the L allele consists of the subtypes of LA allele and LG
allele. The LG allele equivalently expresses HTT mRNA with
similar function as a short (S) variant. As a result, similar to the
S allele, the LG allele has low serotonin transporter expression and
serotonin reuptake activity. If there are many LG in S/L and L/L
genotypes, the effect of 5-HTTLPR might have been under-
estimated (Hu et al. 2006). For more detailed comparison, con-
sideration should be given to the fact that 5-HTTLPR is
functionally triallelic. Thakur et al. (2010) have suggested that the
LG allele is functionally equivalent to the S allele (Thakur et al.
2010). They investigated the association of clinical response to
MPH treatment in children with ADHD by categorizing both LG/LG
and S/LG genotypes into the S/S group, LG/LA and S/LA into the S/L
group, and LA/LA into the L/L group. Third, recent studies suggest
that the 5-HTTLPR polymorphism could moderate the effect of
environmental stressors (Nikolas et al. 2010; Jonassaint et al. 2012;
van der Meer et al. 2014). However, we could not investigate the
effect of environmental factors with our study design.
Van derMeer et al. (2014) found that neither the genetic factor of
5-HTTLPR polymorphism nor the environmental factor of stress
could independently affect symptoms in children or young adults
with ADHD, but that they did affect symptoms by interacting with
each other (van der Meer et al. 2014). In particular, a positive
correlation between stress and ADHD severity was reported in
S allele carriers. This is consistent with the existing theories sug-
gesting that carrying the S allele associated with anxiety-related
traits and higher reaction to stress (such as increased heart rate and
increased blood flow in the limbic system) is linked to stress and the
resultant negative results (Lesch et al. 1996; Muller et al. 2008;
Caspi et al. 2010). We did not consider the possibility that the
S allele could aggravate ADHD symptoms by the mediation of
stress, therefore affecting the clinical response.
Although the association between 5-HTTLPR polymorphism
and the clinical response to MPH treatment was not confirmed in
our study, we did find that the more L variants there were, the more
correlations there were between 5-HTTLPR polymorphism and tics
and nail biting (possible side effect of MPH treatment). It is well
known that ADHD has a high comorbidity with tic disorder
(Taurines et al. 2010; El Malhany et al. 2015). Until recent years,
whether the use of the stimulants causes or aggravates tic symptoms
has been a debated issue. It is a common view that using stimulants
in children with ADHD does not cause tic symptoms. However,
there is a strong association between stimulant use and tic symp-
toms (Lowe et al. 1982; Kurlan 2003; Erenberg 2005). In addition,
the high comorbidity rate of ADHD, tic disorder, and obsessive-
compulsive disorder (OCD) suggests a genetic relationship among
these disorders (Gillberg et al. 2004; Taurines et al. 2010). A family
study suggests that OCD and tic disorder are considered to share
genetic susceptibility factor, whereas the association between
ADHD and tic disorder is more complicated. Such association
might be mediated in part by OCD (Mathews and Grados 2011;
O’Rourke et al. 2011).
More recently, however, 5-HTTLPR, a candidate gene for
ADHD and OCD, was found to be a candidate gene in Tourette
disorder as well. Moya et al. (2013) revealed a relationship between
the LA allele or LAC haplotype of 5-HTTLPR polymorphism
(5-HTTLPR/rs25531/rs25532) and Tourette disorder. By increas-
ing serotonin clearance, the LA allele and LAC haplotype caused
low serotonin levels and upregulated postsynaptic 5-HT2A recep-
tor (Moya et al. 2013). Such a change in the serotonin receptor is
reported to increase the secretion of dopamine, affecting the onset
of Tourette disorder (Cath et al. 2001).
In this study, the reason that the group with the L allele showed
a new onset or aggravation of tic symptom could be because
5-HTTLPR polymorphism indirectly affected the dopaminergic
system. It is also possible that the etiologies of ADHD and OCD, as
well as those of ADHD and tic disorder, are genetically linked to-
gether. Meanwhile, nail biting known as body-focused repetitive
behavior disorder has a tendency to be transmitted in the family of the
patients with OCD, which is considered to be part of familial OCD
spectrum (Bienvenu et al. 2000). Although there is no consensus yet,
the LA allele of 5-HTTLPR is associated with OCD (Taylor 2013). In
addition, the LA allele of 5-HTTLPR has a strong association with
early onset OCD, with younger age having more power to explain the
genetic etiology (Walitza et al. 2014). Because nail biting as an OCD
spectrum disorder partly shares 5-HTTLPR polymorphism, it might
be more sensitive to dopamine and/or serotonin turnover change
when MPH is administered. In this study, there was no difference in
baseline tic symptoms between the S/S and S/L+L/L groups, but the
existence of a significant difference in tic symptoms between the two
groups after MPH treatment suggests that there was significant as-
sociation between 5-HTTLPR polymorphism and the occurrence of
tics and nail biting as adverse events of MPH treatment in ADHD
children. However, we cannot disentangle the causal relationship
between the MPH treatment and the occurrence of tics with our
current study design. The association betweenMPH treatment and tic
symptom is complicated. We cannot exclude the possibility that
multiple factors, such as genetic predisposition, including 5-HTTLPR
L genotype, and stimulant treatment or stress, may trigger tic
symptoms in ADHD children by interacting with each other.
Limitations
Our study has the following limitations. First, a relatively small
sample size made it impossible to obtain statistical significance. In
complex neuropsychiatric disorders, including ADHD, sample si-
zes in at least the thousands or tens of thousands are necessary to
expect a robust finding from a candidate gene study in ADHD, and,
therefore, our findings need to be replicated in larger samples. In
addition, the samples were biased in terms of gender, as male
participants accounted for 80% of the whole sample. However,
there was no difference in the ratio of gender between the two
groups. Second, our study design is not a randomized placebo-
controlled study, and, therefore, is not able to exclude the effect of
placebo response. Third, our findings may be difficult to generalize
to other races and ethnic groups. Based on a previous study that
reported a 5-HTTLPR allelic frequency difference among different
ethnicities — the lower L allele frequency in Asian populations
compared with those of European or African descent (Goldman
et al. 2010) — our results about the effectiveness and adverse
events of MPH treatment may not be generalized across different
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populations. Fourth, in our sample, ADHD’s comorbidity with
disruptive behavior disorders (for example, CD or ODD) was rel-
atively low (at 6.2%), whereas that with internalizing disorders (for
example, mood disorder or anxiety disorder) was higher (at 28%).
Compared with the ADHD comorbidity in the previous study
(Biederman 2005), the ratio of disruptive behavior disorder in this
study was relatively lower. However, no significant difference was
found between the two genotype groups. Fifth, when evaluating
side effects in patients, we did not use an objective scale tool such
as the Side Effect Rating Scale (SRS). However, well-trained
psychiatrists have carefully examined their side effects through
parents’ reports and clinical interviews with the subjects.
Conclusions
In conclusion, our results revealed that there was no significant
association between 5-HTTLPR polymorphism and the response to
MPH treatment in ADHD children. There has been report of in-
consistent results for this issue in previous studies. Further studies
are needed to clarify this issue. Given the fact that 5-HTTLPR is
triallelic, the genotypes should be grouped in a more refined way. In
addition, the effect of environmental factors should be considered.
However, we did find that the S/L or L/L genotypes of 5-HTTLPR
polymorphism were associated with tics after MPH treatment.
Carrying L alleles could affect serotonin transporter gene expres-
sion by indirectly accelerating dopamine release through the se-
rotonergic pathway. This may aid in our understanding of the
genetic contribution and genetic susceptibility of this particular
allele in those ADHD patients with tics.
Clinical Significance
To our best knowledge, our result is the first one to show the
relationship between the serotonin transporter gene and tics after
treatment with MPH in ADHD children.
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